冠状动脉钙化评分对接受根治性放疗的局部晚期非小细胞肺癌患者总生存期是否有影响
研究纳入2014—2015年丹麦644例接受根治性放疗的局部晚期非小细胞肺癌患者,利用放疗计划CT手动测量冠状动脉钙化评分(CACs)并分为0、1-99、100-399、≥400四组。中位随访7年,中位总生存期26个月(95%CI 24-29)。单因素分析中生存随CACs升高而下降,但校正年龄、体能状态、放疗剂量和对数GTV后,CACs对总生存期无统计学显著影响。
要点
- 644例局部晚期非小细胞肺癌患者按CACs分为0、1-99、100-399、≥400四组,例数分别为172、182、143、147例。
- 中位随访7年,中位总生存期26个月(95%CI 24-29)。
- 校正年龄、PS、放疗剂量和对数GTV后,CACs对总生存期无统计学显著影响。
核心结论
- CACs未能在本研究人群中为肿瘤体积、体能状态和年龄等经典危险因素增加预后信息,尽管存在基线心脏合并症风险,肺癌仍是最高优先。
研究设计与样本
- 研究纳入2014—2015年在丹麦治疗的644例局部晚期非小细胞肺癌患者,基线特征来自丹麦肺癌登记处。
- 利用放疗计划CT扫描手动测量CACs,将患者分为CACs 0、1-99、100-399和≥400四组。
- 采用多变量Cox模型并结合bootstrapping进行交叉验证来建模总生存期。
主要发现
- 中位随访时间为7年,中位总生存期为26个月(95%CI 24-29)。
- CACs 0、1-99、100-399和≥400组分别有172、182、143和147例患者。
- 单因素分析中,生存随CACs升高而下降。
- 校正年龄、PS、放疗剂量和对数GTV后,CACs 1-99、100-399和≥400组对总生存期的风险比分别为1.04(95%CI 0.85-1.28)、1.11(95%CI 0.89-1.43)和1.16(95%CI 0.92-1.47),未达统计学显著。
- 73%的患者观察到CACs升高,提示放疗前心脏合并症风险高。
关键数值与推荐
- CACs分组界值为0、1-99、100-399和≥400。
- 校正后CACs 1-99组风险比1.04(95%CI 0.85-1.28),CACs 100-399组风险比1.11(95%CI 0.89-1.43),CACs≥400组风险比1.16(95%CI 0.92-1.47)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Coronary artery calcium score (CACs) is an excellent marker for survival in non-cancer patients, but its role in locally advanced non-small cell lung cancer (LA-NSCLC) patients remains uncertain. In this study, we hypothesize that CACs is a prognostic marker for survival in a competing risk analysis in LA-NSCLC patients treated with definitive radiotherapy. MATERIALS AND METHODS: We included 644 patients with LA-NSCLC treated in 2014-2015 in Denmark. Baseline patient characteristics were derived from the Danish Lung Cancer Registry. Radiotherapy planning CT scans were used for manual CACs measurements, and the patients were divided into four groups, CACs 0, 1-99, 100-399, and ≥400. A multivariable Cox model utilizing bootstrapping for cross-validation modeled overall survival (OS). RESULTS: The median follow-up time was seven years, and the median OS was 26 months (95% CI 24-29). Within each CAC group 0, 1-99, 100-399, and ≥400 were 172, 182, 143, and 147 patients, respectively. In the univariable analysis, the survival decreased with increasing CACs. However, after adjustment for age, PS, radiotherapy dose, and logarithmic GTV, CACs did not have a statistically significant impact on OS with hazard ratios of 1.04 (95% CI 0.85-1.28), 1.11 (95%CI 0.89-1.43), and 1.16 (95%CI 0.92-1.47) for CACs 1-99, CACs 100-399 and ≥400, respectively. Elevated CACs was observed in 73 % of the patients suggesting a high risk of cardiac comorbidity before radiotherapy. CONCLUSION: CACs did not add prognostic information to our population's classical risk factors, such as tumor volume, performance status, and age; the lung cancer has the highest priority despite the risk of baseline cardiac comorbidity.
引用
- Olloni A, Brink C, Lorenzen EL, et al. Does coronary artery calcium score have an impact on overall survival for locally advanced non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol. 2023. PMID: 37257588. doi:10.1016/j.radonc.2023.109719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。